Janet Woodcock’s tenure as director of the US Food and Drug Administration’s Center for Drug Evaluation and Research ended only three years ago, but some in Congress already are nostalgic for what they characterized as a bygone era.
Woodcock Nostalgia: GOP Rep. Bilirakis Wants CDER To Recapture Her Flexible Approach
Energy and Commerce Committee member suggests CBER now is more flexible with rare disease product approval requirements than CDER, inviting the drug center to return to its approach under former director Janet Woodcock.
More from Rare Diseases
More from Pink Sheet
• By
Pink Sheet reporter and editors discuss how the massive layoffs will reshape the FDA and its impact on the drug and biologics industries.
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.